Revenue segments as reported by the company.

Waters

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative expenses

Research and development expenses

Purchased intangibles amortization

Asset impairment

Litigation provision

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Waters Corp. engages in the provision of workflow solutions involving liquid chromatography, mass spectrometry, and thermal analysis. It operates through the Waters and TA (TA Instruments) segments. The Waters segment consists of liquid chromatography instruments, mass spectrometry, and precision chemistry consumable products and services. The TA segment products and services include thermal analysis, rheometry and calorimetry instrument systems, and service sales. The company was founded by James Logan Waters in 1958 and is headquartered in Milford, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Waters reports robust Q4 earnings, eyes growth through acquisitions

Waters Corporation's strong performance in Q4 2022 and full-year results, coupled with the Wyatt Technology acquisition, positions the company for continued growth.
Despite challenges in China and FX headwinds, Waters sees opportunities in pricing increases, revenue synergies from acquisitions, and growth in bioanalytical applications.

Waters Corp reports Q1 revenue growth below expectations, eyes biotech

Waters Corporation faces challenges from weaker demand in key sectors but maintains strengths in certain divisions and sustainability efforts. The acquisition of Wyatt Technology presents growth opportunities, with a focus on maintaining pricing strength and capitalizing on ongoing pharma activity.

Waters (WAT) reports robust Q2 growth, eyes Chinese market recovery

Waters Corporation delivered strong Q2 performance with 5% constant currency growth and non-GAAP EPS above expectations, driven by operational excellence and margin expansion.
While challenges persist in the China Pharma market and cautious spending trends impact growth outlook, Waters remains well-positioned for growth above market rates.
The company's strategic strengths in innovation, execution, and margin expansion, coupled with growth opportunities in key segments and regions, position it for continued success.

Waters expands margins amidst China challenges, eyes service growth

Waters Corporation navigated through challenges in China, focusing on margin expansion, cost management, and workforce optimization. Despite headwinds, the company showcased resilience, positive cash flow, and growth opportunities in service attachment rates and e-commerce sales.

Waters faces sales decline in Q4 2023, eyes PFAS market

Waters navigated a challenging Q4 2023 with sales decline and cautious Q1 2024 guidance. Despite China's struggles, the company's operational resilience and focus on sustainability are strengths. Opportunities lie in PFAS testing, e-commerce growth, and large molecule applications.

Waters Corp exceeds EPS guidance, eyes China stimulus for growth

Waters Corporation's Q1 2024 performance was solid, with a focus on margin expansion and innovation. Challenges include sales decline and concerns about revenue targets. Opportunities exist in China's pharma market stabilization and margin progression.

Waters Corporation surpasses Q2 expectations, eyes long-term growth strategies

Waters Corporation delivered strong Q2 results, exceeding expectations with resilient margins.
While facing sales declines, the company showcased operational efficiency and strategic focus.
Guidance reflects caution on ex-China markets but highlights opportunities for growth.
Strategic flexibility in debt management and product innovation position the company for long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MILFORD, Mass.--(BUSINESS WIRE)-- #mabs--The Waters™ BioAccord™ LC-MS System enables laboratories to monitor critical quality attributes of protein-based drugs.

Waters Peptide Multi-Attribute Method for BioAccord System Boosts Innovator and Biosimilar Drug Development and Commercialization

MILFORD, Mass.--(BUSINESS WIRE)-- #massspec--The compact Waters ACQUITY RDa Detector features SmartMS technology making it easy to obtain accurate-mass measurements on small molecules.

Waters Improves Ease and Reliability of Small Molecule Analysis with ACQUITY RDa Detector

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) today announced it has entered a reseller agreement with TetraScience, a cloud technology innovator powering transformational changes in life sciences R&D. Through the partnership, Waters will now offer its customers the Empower™ Data Science Link, powered by TetraScience. This unique technology pairs Waters' industry-leading, compliance-ready Empower Chromatography Data System (CDS) with TetraScience's Data Platform and data sc

Waters and TetraScience Partner to Deliver New Levels of Data Access and Insights with Empower Data Science Link

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) Udit Batra Ph.D., President and Chief Executive Officer, will speak to the investment community at the Cowen Healthcare Conference virtually on Wednesday, March 3rd, 2021 at 2:40PM Eastern Standard Time. Interested investors can access the live webcast of the presentation by logging on to Waters Corporation's website www.waters.com in the investor relations' section and clicking on “Cowen Healthcare Conference.” About Waters Corpora

Waters Corporation Presentation at the 41st Annual Cowen Healthcare Conference to Be Audio Webcast Live

Emerson Electric

ManpowerGroup

M.D.C. Holdings

Panasonic Holdings Corp

Buy-ranked stocks that just reported positive surprises are what you should be buying.

These 5 Buy-Ranked Companies Just Posted Solid Earnings Beats

Waters Corporation's (WAT) CEO Udit Batra on Q4 2020 Results - Earnings Call Transcript

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE: WAT) today announced fourth quarter 2020 sales of $787 million, a 10% increase as reported, compared to sales of $716 million for the fourth quarter of 2019. Foreign currency translation benefited sales growth by approximately 3% for the quarter. On a GAAP basis, diluted earnings per share (EPS) for the fourth quarter of 2020 increased to $3.49, compared to $3.12 for the fourth quarter of 2019. On a non-GAAP basis, EPS increased to $3.6

Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2020 Financial Results

Waters Corp (WAT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Waters Corp (WAT) This Earnings Season?

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) today announced that it received a score of 95 out of 100 on the 2021 Corporate Equality Index (CEI), the Human Rights Campaign Foundation's annual scorecard for LGBTQ workplace equality. This first-time recognition for Waters is a testament to the company's ongoing global commitment to diversity and inclusion. The Human Rights Campaign Foundation's CEI is the nation's foremost benchmarking survey and report measuring corporate poli

Waters Corporation Recognized for Commitment to Diversity and Inclusion by the Human Rights Campaign Foundation

Bruker

Mettler-Toledo

PerkinElmer

4 Stocks to Watch on Rising Demand for Scientific Instruments

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) will webcast its Q4 2020 financial results conference call live on Tuesday, February 2, 2021 at 8:00 a.m. eastern time. To listen to the conference call, connect to Waters' website, www.waters.com choose “Investors” and click on the Live Webcast. A replay of the webcast will be available until Feb 9, 2021 at midnight eastern time. About Waters Corporation Waters Corporation (NYSE:WAT), the world's leading specialty measurement compa

Waters Corporation Q4 2020 Financial Results Webcast Invitation

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) Udit Batra Ph.D., President and Chief Executive Officer, will speak to the investment community at the J.P. Morgan Healthcare Conference virtually on Tuesday, January 12th, 2021 at 8:20AM Eastern Standard Time. Interested investors can access the live webcast of the presentation by logging on to Waters Corporation's website www.waters.com in the investor relations' section and clicking on “J.P. Morgan Healthcare Conference.” About W

Waters Corporation Presentation at the 39th Annual J.P. Morgan Healthcare Conference to Be Audio Webcast Live

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) today announced that Dr. Pearl S. Huang, President and CEO of Cygnal Therapeutics and venture partner at Flagship Pioneering, has been appointed as a Director of Waters Corporation, effective January 1, 2021. “We are pleased to welcome Pearl to the Waters Board of Directors,” said Dr. Flemming Ornskov, Chairman of the Board. “Pearl is a distinguished executive with significant scientific expertise in the discovery of biologics, smal

Waters Corporation Appoints Pearl S. Huang to Board of Directors

DAEGU, South Korea--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) has formally expanded its long-standing, collaborative relationship with Dr. Sunghwan Kim of Kyungpook National University to further explore the use of Waters' cutting-edge ion mobility spectrometry (IMS) in the investigation of compounds in complex mixtures. Identifying unknown chemicals in complex organic media at the molecular level has become an important but difficult research topic in modern analytical chemistry. For exam

Waters Collaborates with Dr. Sunghwan Kim of Kyungpook National University to Advance Precision Analysis of Complex Chemical Compounds

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) today announced that Sherry Buck will step down as Chief Financial Officer, effective December 31, 2020, in order to pursue another opportunity at a privately held company. Upon her departure, Michael F. Silveira, Vice President and Corporate Controller of Waters, will assume the role of interim Chief Financial Officer. Ms. Buck will work alongside Mr. Silveira in order to facilitate a smooth transition. Waters has been actively wor

Waters Corporation Announces CFO Transition

Waters Corporation occupies a leading position in attractive markets. Historically, the company has outperformed the S&P 500 by a wide margin.

Waters: Analyze This

Extra Space Storage

Freeport-McMoRan

Alphabet

Jazz Pharmaceuticals

Eli Lilly

Medtronic

Parker-Hannifin

Royal Caribbean Cruises

Walmart

It is almost hard to believe, in what has been one of the most unbelievable years in recent history, that Halloween is this weekend and Thanksgiving is right around the corner.

BofA Securities Top 10 US Stock Ideas for the Rest of 2021

Waters Corporation (WAT) CEO Udit Batra on Q3 2020 Results - Earnings Call Transcript

Waters (WAT) delivered earnings and revenue surprises of 13.09% and 8.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Waters (WAT) Q3 Earnings and Revenues Surpass Estimates

Shares of Waters (NYSE:WAT) moved higher by 0.1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 1.41% year over year to $2.16, which beat the estimate of $1.93.

Recap: Waters Q3 Earnings

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE: WAT) today announced third quarter 2020 sales of $594 million, a 3% increase as reported, compared to sales of $577 million for the third quarter of 2019. Foreign currency translation benefitted sales growth by approximately 1% for the quarter. On a GAAP basis, diluted earnings per share (EPS) for the third quarter of 2020 decreased to $2.03, compared to $2.07 for the third quarter of 2019. On a non-GAAP basis, EPS increased to $2.16, c

Waters Corporation (NYSE: WAT) Reports Third Quarter 2020 Financial Results

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) will webcast its Q3 2020 financial results conference call live on Tuesday, October 27th at 8:00 a.m. eastern time. To listen to the conference call, connect to Waters’ website, www.waters.com choose “Investors” and click on the Live Webcast. A replay of the webcast will be available until November 3rd at midnight eastern time. Waters Corporation (NYSE:WAT), the world's leading specialty measurement company, has pioneered chromatogr

Waters Corporation Q3 2020 Financial Results Webcast Invitation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) announced this week at Biotech Week Boston the establishment of Immerse™ Cambridge, a new Waters' research laboratory in the heart of Cambridge’s Kendall Square. Immerse Cambridge will serve as a strategic, collaborative space in the community, where Waters can partner with academia, research and industry to accelerate the next generation of scientific advancements. “Immerse Cambridge will house the latest analytical instruments a

Waters Establishes Flagship Innovation and Research Laboratory in Cambridge, MA

BOSTON--(BUSINESS WIRE)-- #DSP--LabMinds, Inc., a pioneer in automation for solution preparation in life sciences, today announced that Waters Corporation (NYSE: WAT), a global leader in specialty measurement in life, food and materials sciences, is outfitting several of its R&D and customer demonstration laboratories with LabMinds’ REVO solution preparation systems.

LabMinds Helps Waters Corporation Enhance Automation and Efficiency of Lab Operations Across Multiple Locations

Waters (WAT) reported earnings 30 days ago. What's next for the stock?

News for Waters Stock (WAT)